

****Published September 2021****

MarketVIEW: Dengue endemic vaccines (CAT: VAMV025)

Product Name	:	MarketVIEW: Dengue endemic vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (>275 slides.pdf) + MS forecast model(s) (.xls)
Therapeutic Area	:	Dengue endemic vaccines
Publication date	:	September 2021
Catalogue No	:	VAMV025

Background

Dengue fever (DF) is a mosquito-borne disease (*Aedes*) caused by single strand RNA viruses of the family *flaviviridae*. DF has a wide spectrum of symptoms ranging from a mild febrile illness to severe outcomes such as hospitalization and death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Latest estimates indicates that **390m** dengue infections occur each year of which **20-30%** are symptomatic (any severity) and **17-49K** deaths occur. It is estimated that **3.9bn** of the world's population are thought to be at risk from dengue infection, mainly urban dwellers in tropical and sub-tropical countries. Importantly, most of the estimated deaths per year are in children (< 15yrs). No specific treatment is available.

A Sanofi Pasteur vaccine (**CYD-TDV, Dengvaxia®**) has been licensed since 2015 for the prevention of disease caused by all four dengue virus serotypes in preadolescents, adolescents and adults, 9 to 45 years of age living in endemic areas. In April 2016, the WHO SAGE committee recommended countries consider introduction of CYD-TDV only in geographic settings (national or subnational) with high endemicity, as indicated by seroprevalence of approximately >70%. Two countries: Brazil (Parana state) and the Philippines started mass immunization programs, albeit with controversy. **Dengvaxia®** is now FDA approved and ACIP recommended but has label restrictions limiting use in those with prior infection (WHO SAGE, April 2018). Other dengue vaccines notably, **TAK-003 (Takeda Vaccines)** and **TetraVAX [TV-003/05 (NIAID, Butantan, Merck & Co)** are in late-stage development, the former of which recently met its Phase III endpoints (filings are imminent).

This **MarketVIEW** product consists of a detailed Executive presentation (>250 slides) and a comprehensive MS-Excel forecast model (250 worksheets) which forecast the potential commercial value of dengue endemic vaccine(s) by competitor across 55 endemic markets to 2036. The model(s) contain value (\$ m) and volume (mio doses) predictions (public and private sector) in adjustable age segments e.g., >4-9 yrs, >18 yrs. LO, BASE and HI forecast scenarios include potential demand from selected country catch-up campaigns and expected approvals from 2022 onwards. An intra state or region roll-out analysis is also included for Brazil and Philippines.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Dengue endemic vaccines in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

Published September 2021 (CAT No: VAMV025)

****This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

Contents – Summary presentation (.pdf) 

Contents

Author's notes

Executive summary

[SECTION 1] Commercial model: key outputs

[SECTION 2] Dengue: disease background

[SECTION 3] Dengue: disease epidemiology

[SECTION 4] Dengue: Dengvaxia® (CYD-TDV) story/data since first approvals

[SECTION 5] Dengue: new vaccines – competitive landscape

[SECTION 6] Dengue: new vaccines – modelling commercial potential

[SECTION 7] Dengue vaccines: case studies, past dengue vaccination

[SECTION 8] Dengue vaccines: backup and source material

References/bibliography

About **VacZine Analytics**

Disclaimer

SNAPSHOT

PAGES: >275 slides fully referenced/sourced. Available in .pdf form

Contents – MS-Excel workbook (.xls) 

United States [Adjustable pediatric and adult target populations, public and private sector]

6 *Island nations*

PAHO region

22 *countries*

Brazil [sub national]

SEA region

11 *countries SNAPSHOT*

WPR region

16 *countries*

Philippines [sub national]

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT [.pdf presentation + MS-Excel] - USD **\$15,995.00**/ GBP **£11,760.00**# (Global license)*

*A region is North America, Europe, or ROW. Global is all 3 regions

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

Licenses are non-exclusive and non-transferable to 3rd parties

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – available upon request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system, or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired while providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd
Warren (Carlton) House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and "the spiral logo" are UK Registered Trademarks, 2009



Since 2007

